Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study

被引:25
|
作者
Ruiz, JC
Diekmann, F
Campistol, JM
Sanchez-Fructuoso, A
Rivera, C
Oliver, J
Fernandez-Fresnedo, G
Arias, M
机构
[1] Univ Cantabria, Mar Valdecilla Hosp, E-39005 Santander, Spain
[2] Hosp Clin Barcelona, Renal Transplant Unit, Barcelona, Spain
[3] Univ Clin Hosp, Dept Nephrol, Madrid, Spain
[4] Juan Canalejo Hosp, Dept Nephrol, Coruna, Spain
[5] Univ Cantabria, Dept Nephrol, E-39005 Santander, Spain
关键词
D O I
10.1016/j.transproceed.2005.09.127
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) has become an option in patients with chronic allograft nephropathy or other conditions. However, in some cases an increase of proteinuria has been reported after such therapeutic intervention. The aim of this study was to characterize the clinical course of this so far unexplained proteinuria after conversion. We performed a retrospective analysis evaluating 94 renal transplant patients from various Spanish centers. Proteinuria (629 determinations) and clinical developments were analyzed between 6 months before and 6 months after conversion. Patients were divided into three groups according to mean proteinuria before conversion (group A: < 300 mg/d; group 13: 300 to 2000 mg/d; and group C: > 2 g/d). The mean proteinuria level was 1.69 g/24 h (n = 312 determinations) before and 2.36 g/24 h after conversion (n = 317 determinations; P=.006), which corresponds to an overall increase of 25% (1.55 to 1.69 g/24 h considering only determinations of 1 month before and 1 month after conversion; P = NS). We could not detect any clear correlation between proteinuria and serum creatinine nor between changes of proteinuria and changes of serum creatinine. A variance analysis for repeated measures showed an increase in proteinuria compared to the preconversion values (P =.003), and when the three groups of preconversion proteinuria were evaluated separately it could be observed that this change in the evolution of proteinuria was almost completely dependent of an increase in the group C (preconversion proteinuria greater than 2 g/d; P =.03), whereas in the other two groups changes were almost irrelevant. Finally, the switch to SRL in renal transplant recipients is followed by an increase in the level of proteinuria predominantly dependent of an increase in patients with high levels of preconversion proteinuria, whereas it seems to be irrelevant in patients without or with light or moderate proteinuria. These results suggest that this might not be a direct effect of SRL.
引用
收藏
页码:3833 / 3835
页数:3
相关论文
共 50 条
  • [21] Outcome of renal-transplant (RT) patients switched from calcineurin inhibitors (CNIS) to sirolimus (SRL) for chronic allograft dysfuntion (CAD)
    Bumbea, V
    Ribes, D
    Kamar, N
    Esposito, L
    Nasou, G
    Modesto, A
    Durand, D
    Rostaing, L
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V166 - V166
  • [22] Conversion to and from sirolimus in renal and hepatic transplant recipients treated with calcineurin inhibitors: Effect on renal function
    Moneim, HA
    Flechner, SM
    Goel, M
    Derweesh, IH
    Modlin, C
    Krishnamurthi, V
    Goldfarb, DA
    Novick, AC
    JOURNAL OF UROLOGY, 2005, 173 (04): : 419 - 419
  • [23] Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
    Backman, L
    Reisæter, AV
    Wramner, L
    Ericzon, BG
    Salmela, K
    Brattström, C
    CLINICAL TRANSPLANTATION, 2006, 20 (03) : 336 - 339
  • [24] Outcome of renal-transplant (RT) patients switched from calcineurin inhibitors (CNIs) to sirolimus (SRL) for chronic allograft dysfuntion (CAD).
    Bumbea, V
    Ribes, D
    Kamar, R
    Esposito, L
    Modesto, A
    Durand, D
    Rostaing, L
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 463 - 463
  • [25] PREDICTORS OF SUCCESSFUL (LATE) CONVERSION FROM CNI TO mTOR INHIBITOR SIROLIMUS (SRL) IN RENAL TANSPLANT RECIPIENTS
    Ramyasuda, Swaminathan
    Rajalingam, Sinnaih
    Ashley, Irish
    IMMUNOLOGY AND CELL BIOLOGY, 2012, 90 (08): : A2 - A3
  • [26] Improvement of renal disfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation
    Hunt, J
    Lerman, M
    Magee, MJ
    Dewey, TM
    Herbert, M
    Mack, MJ
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (11): : 1863 - 1867
  • [27] Long Term Follow up after Conversion from Calcineurin Inhibitors to Sirolimus in a South African Renal Transplant Population
    Parag, Bhavisha
    Assounga, Alain Guy
    TRANSPLANTATION, 2018, 102 : S586 - S587
  • [28] Conversion From Calcineurin Inhibitors to Sirolimus in Kidney Transplant Recipients: A Retrospective Cohort Study
    Cardinal, H.
    Froidure, A.
    Dandavino, R.
    Daloze, P.
    Hebert, M. J.
    Colette, S.
    Boucher, A.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (08) : 3308 - 3310
  • [29] Conversion to and from sirolimus in renal and hepatic transplant recipients treated with calcineurin inhibitors: Effect on renal function.
    Moneim, HA
    Flechner, SM
    George, P
    Derweesh, IH
    Modlin, C
    Krishnamurthi, V
    Goldfarb, D
    Novick, AC
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 376 - 377
  • [30] The Efficacy and Limitations of Sirolimus Conversion in Liver Transplant Patients Who Develop Renal Dysfunction on Calcineurin Inhibitors
    Patrick Lam
    Atsushi Yoshida
    Kimberly Brown
    Marwan Abouljoud
    Iman Bajjoka
    Fadi Dagher
    Dilip K. Moonka
    Digestive Diseases and Sciences, 2004, 49 : 1029 - 1035